A Phase 2 interventional study of MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks and Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks in Diabetes Mellitus, Type II, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-28.
Sponsored by Merck Sharp & Dohme LLC · Phase 2, Interventional, and Treatment
A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 743 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
To asses the effectiveness of MK0431 compared to placebo
Time frame: over 12 weeks
To test the safety and tolerability of MK0431 in patients with type 2 diabetes
No study locations are listed for this record.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC